BrainsWay Company Top Insiders

BRSYF Stock  USD 8.53  0.00  0.00%   
BrainsWay employs about 118 people. The company is managed by 10 executives with a total tenure of roughly 24 years, averaging almost 2.0 years of service per executive, having 11.8 employees per reported executive. Examination of BrainsWay's management performance can provide insight into the company performance.
Avner Hagai  President
Founder and President and Director
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BrainsWay. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For more detail on how to invest in BrainsWay Pink Sheet please use our How to Invest in BrainsWay guide.

BrainsWay Management Team Effectiveness

The company has return on total asset (ROA) of (0.0751) % which means that it has lost $0.0751 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2021) %, meaning that it generated substantial loss on money invested by shareholders. BrainsWay's management efficiency ratios could be used to measure how well BrainsWay manages its routine affairs as well as how well it operates its assets and liabilities.

BrainsWay Workforce Comparison

BrainsWay is rated third in number of employees category among its peers. The total workforce of Medical Devices industry is currently estimated at about 1,326. BrainsWay holds roughly 118 in number of employees claiming about 9% of all equities under Medical Devices industry.
The company has Profit Margin (PM) of (0.37) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.29) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.29.

BrainsWay Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. BrainsWay Price Series Summation is a cross summation of BrainsWay price series and its benchmark/peer.

BrainsWay Notable Stakeholders

A BrainsWay stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as BrainsWay often face trade-offs trying to please all of them. BrainsWay's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting BrainsWay's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Avner HagaiFounder and President and DirectorProfile
Yiftach RothFounder, Chief Scientist and DirectorProfile
Menachem EsqGen VPProfile
Christopher JakoPres CEOProfile
Christopher BoyerVP MarketingProfile
Hadar LevyVP COOProfile
Moria AnkriVP RDProfile
Aron TendlerChief OfficerProfile
Pr ZangenMember CoFounderProfile
Richard AregladoVP CFOProfile

About BrainsWay Management Performance

The success or failure of an entity such as BrainsWay often depends on how effective the management is. BrainsWay management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of BrainsWay management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the BrainsWay management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel. Brainsway operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 118 people.

BrainsWay Workforce Analysis

Traditionally, organizations such as BrainsWay use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare BrainsWay within its industry.

BrainsWay Manpower Efficiency

Return on BrainsWay Manpower

Revenue Per Employee251.3K
Revenue Per Executive3M
Net Loss Per Employee54.8K
Net Loss Per Executive646.2K
Working Capital Per Employee84.7K
Working Capital Per Executive1000K

Complementary Tools for BrainsWay Pink Sheet analysis

When running BrainsWay's price analysis, check to measure BrainsWay's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BrainsWay is operating at the current time. Most of BrainsWay's value examination focuses on studying past and present price action to predict the probability of BrainsWay's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BrainsWay's price. Additionally, you may evaluate how the addition of BrainsWay to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules